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Background: The impact of nicorandil as adjunctive therapy for percutaneous coronary intervention (PCI) in
patients with ST-elevation myocardial infarction (STEMI) is controversial. We performed 15O-labeled water
positron emission tomography (PET) to quantify regional myocardial perfusion in patients with STEMI who
received nicorandil or no adjunctive therapy during PCI.
Methods: PCI was performed within 8 h after STEMI onset in 33 patients. 14 patients received intracoronary
nicorandil 2 mg immediately after recanalization of the culprit lesion (Nico group). After 3–4 weeks, PET was
performed in whichmyocardial blood ﬂow (MBF) was measured at baseline and during adenosine triphosphate
(ATP)-induced hyperemia. Myocardial vascular resistance (MVR) was calculated for all segments. Data were
obtained from the reperfused (Rep) and normal segments (Cont) in each patient.
Results: In patients not given nicorandil (No-Nico group), theMBFwas signiﬁcantly lower inRep than that in Cont
at baseline and during hyperemia (Cont vs. Rep: 0.82 ± 0.14 vs. 0.68 ± 0.11, P= 0.001, ATP-Cont vs. ATP-Rep:
2.00 ± 0.72 vs. 1.52 ± 0.61, P = 0.017), which was restored in the Nico group (Cont vs. Rep: 0.79 ± 0.17 vs.
0.78± 0.20; ATP-Cont vs. ATP-Rep: 2.02±0.84 vs. 1.84± 0.62).MVRwas elevated in Rep at baseline and during
hyperemia in the No-Nico group. MVR elevation in Rep was prevented in the Nico group.
Conclusions: 15O-labeled water PET was feasible for segmental analysis of MBF during the subacute phase of
STEMI. It revealed that intracoronary administration of nicorandil to STEMI patients who underwent PCI
prevented MVR elevation and thus restored MBF in the reperfused segments to a level similar to that in the
normal segments.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nicorandil is a potassium channel opener with nitrate-like actions
that dilate coronary arteries. This agent is also known to prevent reper-
fusion injury and promote ischemic preconditioning [1]. It has been
expected to reduce infarction size and improve clinical outcomes in
patients with acute myocardial infarction [2,3]. The value of nicorandil
as an adjunctive therapy to primary PCI, however, is still controversial.and Cerebrovascular Medicine,
e, Miki-cho, Kita-gun, Kagawa
2151.
d Ltd. This is an open access article unIn fact, a randomized clinical trial showed that intravenous or
intracoronary injection of nicorandil after coronary reperfusion did
not reduce infarct size as assessed with a total creatine kinase leak [4,
5]. In contrast, several reports have shown salutary effects on coronary
perfusion and clinical outcomes by intravenous administration before
reperfusion or intracoronary administration during primary PCI [6,7].
Sakata et al. have reported that intracoronary administration of
nicorandil improved incomplete restoration of myocardial perfusion
after coronary revascularization and functional recovery of the jeopar-
dized myocardium, as shown by myocardial contrast echocardiography
in convalescents [8]. Ishii et al. reported that single intravenous admin-
istration of nicorandil before reperfusion improved coronary ﬂow as
evaluated by the corrected thrombolysis in myocardial infarctionder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cardiovascular events and death in patients with ST-elevation myocar-
dial infarction (STEMI) [9]. This may explain why the administration
of nicorandil has shown inconsistent outcomes in patients with
STEMI. The studies have provided different timing for nicorandil admin-
istration and/or different methods for evaluating myocardial perfusion.
Positron emission tomography (PET) with 15O-labeled water is a
noninvasive method for accurately quantifying regional myocardial
blood ﬂow (MBF) presented as the regional perfusion (mL·min−1)
per gram of myocardium [10,11]. This method has been validated in
previous reports [12,13]. Previous studies showed a reduction of basal
MBF in patients who smoked or had diabetes mellitus. Furthermore,
there are still concerns regarding confounding factors affecting MBF
such as hypertension, dyslipidemia, sex, and age [14,15]. Therefore, to
clarify the effect of nicorandil on MBF, it is important to measure the
MBF in the normal segments to compare them with the reperfused
segments of the left ventricle in each patient. This study was designed
to estimate MBF in all segments at basal and during adenosine triphos-
phate disodium hydrate (ATP)-induced hyperemia. ATP is a short-
acting drug that mainly dilates the coronary arterial smooth muscle.
Therefore, ATP-induced hyperemic blood ﬂow is used to evaluate the
coronary vasculature [16].
Based on these previous studies, themain aimof this study is to eval-
uate the regional myocardial blood ﬂow in the reperfused segments
compared with those in the normal segments by 15O-labeled water
PET after intracoronary administration of nicorandil during percutane-
ous coronary intervention (PCI) procedures in patients with STEMI.
2. Materials and methods
The eligibility criteria were the presence of STEMI in a patient
admitted to the hospital within 8 h of the onset of symptoms. The
exclusion criteria were a history of myocardial infarction; left main
trunk stenosis; severe liver or kidney dysfunction, or both; suspected
aortic dissection; previous coronary artery bypass grafting; and/or a
history of drug allergy. All patients gave written informed consent
immediately after admission to the hospital.
The Institutional Review Board and Ethics Committee of Kagawa
University Hospital approved the study protocol in accordance with
the Declaration of Helsinki.
We introduced an adjunctive treatment with nicorandil to the
standard PCI. Nicorandil 2 mg was given by intracoronary injection im-
mediately after recanalization of the culprit lesion. We applied this
treatment to 14 consecutive patients from June 2011, who comprised
the nicorandil (Nico) group. An earlier group of 19 consecutive patients
who underwent standard primary PCI only, served as the no-nicorandil
(No-Nico) group. The difference between the two groups was the pres-
ence or absence of the adjunctive treatment with intracoronary admin-
istration of nicorandil. Standard PCI, including nitrate administration,
was performed in all patients within 8 h after the onset of STEMI.
We evaluated the regional MBF and myocardial vascular resistance
(MVR) by 15O-labeled water PET between 3 and 4 weeks after PCI.
MVR is calculated as the mean arterial blood pressure divided by the
MBF. For the analysis of MBF, we performed segment-based measure-
ments. As shown in Fig. 1, the left ventricle was divided into 16
segments according to the model recommended by the American
Society of Echocardiography and American Heart Association [17].
These segments included the anterior, anteroseptal, septal, inferior,
posterior, and lateral walls, where each was subdivided into basal and
mid portions, as well as the anterior apex, septal apex, inferior apex,
and lateral apex. Data were obtained from each segment, and MBF
was calculated by mean value in each coronary artery territories [18].
Furthermore, to avoid the effect of ischemia on MBF, we categorized
themyocardial segments into three groups according to themost recent
coronary angiography before the 15O-labeledwater PET: those perfused
insufﬁciently by a stenosed coronary artery (Ischemia group); thosewith a nonstenosed coronary artery (controls, Cont); and those
reperfused by PCI (Rep). The deﬁnition of stenosis is more than 75% of
stenosis according to the deﬁnition of the American Heart Association
[19]. The Ischemia group was excluded from the analysis.
2.1. PET image processing.
PET image processing and analysis were accomplished as described
previously [20]. PET was performed using a whole-body scanner
(Siemens/CTI, Knoxville, TN, USA) equipped with germanium-68
retractable line sources for transmission scans. All emissions and
transmissions were reconstructed using ﬁltered back-projection. The
full-width at half maximum at the center of the ﬁeld of view was
4.7 mm. The optimal imaging positron was determined by a 5-min
rectilinear scan after exposure of an external 68Ga ring source. A 6-min
transmission scan was then acquired for the purpose of attenuation
correction of all subsequent emission scans.
Blood volume images were produced in the following manner.
During the5-min scanningperiod, venous blood sampleswere obtained
every 2min, and radioactivity in thewhole bloodwasmeasuredwith an
automatic gamma counter (Fukuda Electric Company, Saitama, Japan).
15O radioactivity returned to background level 15 min after the
blood volume scan. Then, 15O-labeled water was slowly (over 2 min)
infused into an antecubital vein. 15O-labeled water was administered
twice during the study. The administered dose of 15O-labeled water
was 500 MBq/min. A 20-frame dynamic PET scan was performed for
6 min consisting of six frames for 5 s, six frames for 15 s, and eight
frames for 30 s.
The MBF (in milliliters per gram per minute) of the whole left
ventricle was measured using 15O-labeled water as the ﬂow tracer and
previously validated 15O radioactivity. We repeated the MBF measure-
ment during ATP-induced hyperemia. ATP was infused for 9 min at
0.16 mg/kg/min, according to a standard protocol. PET acquisition was
started 3 min after beginning the ATP infusion. Blood pressure was
recorded at 1-min intervals. The patient's electrocardiogram was
monitored continuously throughout the procedure at baseline and
every minute during ATP administration.
2.2. Production of 15O-labeled water PET
A low-energy deuteron accelerator was used to produce the 15O
compounds (CYPRIS-HM18 cyclotron; Sumitomo Heavy Industries,
Tokyo, Japan). 15O-labeled water was produced with a dialysis tech-
nique in a continuously working water module. Sterility and pyrogen
tests were performed daily to verify the purity of the product.
2.3. Statistical analysis
Data were analyzed using SPSS version 21 (SPSS Inc., Chicago, IL,
USA). All data are expressed as the mean ± standard deviation. The
baseline clinical and angiographic characteristic parameters between
the Nico group and the No-Nico group in all groups were compared
with an unpaired t-test. The MBF and MVR at baseline and during
ATP-induced hyperemia were compared in each group with the
unpaired t-test. The PET-derived parameters (MBF and MVR) were
compared between the two groups by repeated-measures analysis of
variance. P b 0.05 was considered statistically signiﬁcant.
3. Results
The baseline characteristics of the patients and the baseline and PET
procedure drug information are shown in Table 1 and 2. There were no
differences between the two groups in PCI procedure. The ratio of pa-
tients with obesity and hyperlipidemia in the No-Nico were signiﬁcant-
ly higher than that in the Non-Nico group.
Fig. 1.Myocardial blood ﬂow images by 15O-labeled water PET using a 16-segment model at rest (left) and during hyperemia (right) in patients with acute inferior myocardial infarction
treated with (a) or without (b) nicorandil to the standard PCI. MBF =myocardial blood ﬂow; PET = positron emission tomography and PCI = percutaneous coronary intervention.
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Table 1
Baseline clinical and angiographic characteristics of the study population.
Nicorandil No-Nicorandil P value
n= 14 n= 19
Age, y 69.9 ± 12.7 63.5 ± 12.0 0.149
Sex, F/M 2/12 5/14 –
BMI, kg/m2 23.3 ± 3.30 22.7 ± 2.35 0.562
Obesity, n (%) 6 (42.9) 2 (10.5) 0.047
Hypertension, n (%) 10 (71.4) 7 (36.8) 0.080
Diabetes mellitus, n (%) 6 (42.9) 6 (31.6) 0.716
Hyperlipidemia, n (%) 9 (64.3) 5 (26.3) 0.040
Smoking, n (%) 8 (57.1) 10 (52.6) 1.000
Onset-to-balloon time (min) 302 ± 148 306 ± 158 0.939
Onset-to-balloon time b 4 h, n 8 (57.1) 10 (52.6) 1.000
TIMI grade before PCI (0/1/2/3), n 9/4/1/0 10/6/3/0 –
Previous PCI, n 1 (7.14) 1 (5.3) 1.000
PTCR, n 0 0 –
Peak CPK, IU 2798 ± 1364 3523 ± 2174 0.281
Final achievement of TIMI ﬂow III grade 14 (100) 18 (94.7) 1.000
Culprit vessel, n (%)
LAD 8 9
LCX 2 2 –
RCA 4 8
PCI procedure
Main vessel
POBA/BMS/DES, n 0/2/10 1/18/0 –
Thromboaspiration, n 8 (57.1) 8 (42.1) 0.491
Stent length, mm 25.7 ± 7.2 19.7 ± 10.4 0.073
Stent diameter, mm 3.14 ± 0.49 3.28 ± 0.36 0.376
Procedure time, min 96.4 ± 28.0 93.2 ± 24.3 0.723
Restenosis at 6 months, n 1 (7.14) 4 (21.1) 0.366
Values aremean± SD or n (%). Nicorandil vs. No-Nicorandil. BMI, bodymass index; PTCR,
Percutaneous Transluminal Coronary Recanalization; TIMI, thrombolysis inmyocardial in-
farction trial; LAD, left anterior descending artery; LCX, left circumﬂex artery; RCA, right
coronary artery; CPK, creatine phosphokinase; LVEF, left ventricular ejection fraction;
PCI, percutaneous coronary intervention; POBA and percutaneous old balloon angioplasty.
Values are mean ± SD or n (%). BMS, bare metal stent and DES, drug eluting stent.
Table 2
Baseline and PET procedure drug information.
Nicorandil No-Nicorandil P value
n= 14 n= 19
Baseline
ARB, n 4 (28.6) 2 (10.5) 0.363
ACE-I, n 0 4 (21.1) 0.119
CCB, n 4 (28.6) 3 (15.8) 0.422
Statins, n 2 (14.3) 0 0.172
Aspirin, n 2 (14.3) 3 (15.8) 1.000
Clopidogrel, n 0 0 –
Ticlopidine, n 0 0 –
Antiplatelet agents, n 2 (14.3) 3 (15.8) 1.000
β-Blocker, n 2 (14.3) 1 (5.3) 0.561
Nitrates, n 2 (14.3) 2 (10.5) 1.000
Nicorandil, n 0 2 (10.5) 0.496
Diuretic, n 0 0 –
At PET procedure
ARB, n 11 (78.6) 11 (57.9) 0.278
ACE-I, n 4 (28.6) 7 (36.8) 0.719
CCB, n 2 (14.3) 2 (10.5) 1.000
Statins, n 13 (92.9) 9 (47.4) 0.009
Aspirin, n 14 (100) 18 (94.7) 1.000
Clopidogrel, n 13 (92.9) 0 0.0001
Ticlopidine, n 0 15 (78.9) 0.0001
Antiplatelet agents, n 14 (100) 19 (100) –
β-Blocker, n 13 (92.9) 4 (21.1) 0.0001
Nitrates, n 1 (7.14) 4 (21.1) 0.366
Nicorandil, n 2 (14.3) 12 (63.2) 0.011
Diuretic, n 4 (28.6) 4 (21.1) 0.695
n(%). Nicorandil vs. No-Nicorandil. ARB, angiotensin II receptor blocker; ACE-I, angiotensin
converting enzyme inhibitor; CCB, calcium channel blocker and PET, positron emission
tomography.
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0.15 mL/min/g (95% conﬁdence interval, 0.74–0.83 mL/min/g) in this
study. Because variations of about 10% of the MBF value were seen
among the patients at baseline, it was important to compare the MBF
in the normal segments with that in the reperfused segments in each
patient.
We collected a total of 137 normal segments in Cont, 82 reperfused
segments in Rep, and 5 exclusion segments from 14 patients in the Nico
group. We also collected a total of 150 normal segments in Cont, 105
reperfused segments in Rep, and 49 exclusion segments from 19
patients in the No-Nico group.
As shown in Fig. 2, in the No-Nico group, the MBF was signiﬁcantly
lower in the reperfused segments than that in the normal segments at
baseline. The differencewas augmentedduringATP-induced hyperemia
(Cont vs. Rep: 0.82± 0.14 vs. 0.68± 0.11, P=0.001; ATP-Cont vs. ATP-
Rep: 2.00 ± 0.72 vs. 1.52 ± 0.61, P = 0.017). In contrast, in the Nico
group, the MBF in the reperfused segments was restored to a level sim-
ilar to those in the normal segments at baseline and duringATP-induced
hyperemia (Cont vs. Rep: 0.79 ± 0.17 vs. 0.78 ± 0.20; ATP-Cont vs.
ATP-Rep: 2.02 ± 0.84 vs. 1.84 ± 0.62, P=NS for both measurements).
The Rep/Cont, which indicates the ratio of salvage of MBF, tended to be
restored in the Nico group at baseline and during ATP-induced hyper-
emia (baseline: No-Nico Rep/Cont vs. Nico Rep/Cont: 0.89 ± 0.24 vs.
0.99 ± 0.23, P = 0.237; ATP: No-Nico Rep/Cont vs. Nico Rep/Cont:
0.77 ± 0.26 vs. 0.92 ± 0.21, P= 0.091).
In addition, to avoid the effect of perfusion pressure on MBF, we
calculated theMVR in all segments. TheMVRwas elevated in the reper-
fused segments at baseline and during ATP-induced hyperemia in the
No-Nico group (Cont vs. Rep: 98.8 ± 22.9 vs. 119.5 ± 32.3, P = 0.01;
ATP-Cont vs. ATP-Rep: 41.6± 17.0 vs. 59.7 ± 35.7, P=0.02). However,
such an elevation of MVR in the reperfused segments was successfully
prevented in the Nico group(Cont vs. Rep: 115.7 ± 33.4 vs. 121.2 ±
34.8; ATP-Cont vs. ATP-Rep: 43.5 ± 17.5 vs. 45.9 ± 20.6) (Fig. 3).
Nevertheless, there was no reduction of the maximum creatine
phosphokinase leak and improvement of the left ventricular ejection
fraction valued by echocardiography during the subacute phase of
myocardial infarction (Nico: 49.0 ± 8.38% vs. No-Nico: 55.0 ± 16.6%).
4. Discussion
We have clearly shown that intracoronary administration of
nicorandil preserved the regional microcirculation in the reperfused
segments in patients with STEMI. One other ﬁnding was that
15O-labeled water PET was feasible for segmental analyses of MBF atFig. 2. Comparison of myocardial blood ﬂow between normal segments and reperfused
segments. *P b 0.05 vs. control segments. MBF =myocardial blood ﬂow; Cont = normal
segments and Rep = reperfused segments.
Fig. 3. Comparison of myocardial vascular resistance between normal control segments
and reperfused segments. *P b 0.05 vs. control segments. MVR=myocardial vascular re-
sistance; Cont = normal segments and Rep = reperfused segments.
85W. Takabatake et al. / IJC Heart & Vasculature 8 (2015) 81–86the subacute phase of STEMI. Although a left bundle branch block
(LBBB) exhibits reduced MBF both at stress and rest [21], there were
no patients with LBBB in this study. Our protocol was quite simple,
involving a single intracoronary injection. The most likely mechanism
for the salutary effects of nicorandil on restoration of MBF might be
that the pharmacologic vasodilation for the coronary vasculature result-
ed in a maintained vascular lumen. Hence, nicorandil prevented in-
creased MVR after reperfusion. Nicorandil increases coronary blood
ﬂow, particularly to small vessels (b100 μm) [22]. It is similar to a
potassium channel opener with nitrate-like actions that dilate coronary
arteries. In the ischemic myocardium, K-ATP channels are activated by
intracellular ATP depletion, with increased outﬂow of potassium,
shortening the duration of the action potential and reducing calcium
inﬂow to myocytes [23]. Inhibition and reduction of calcium inﬂow to
myocytes may have cardioprotective effects on the ischemic heart,
and K-ATP channel openers help this action [24]. In one study,
mitochondrial K-ATP channels were further shown to be related to
preconditioning as the end factor of many signal transduction systems.
Thus, nicorandil might exert salutary effects through its activation [25].
The timing of intracoronary administration of nicorandilmight be an
important factor for decreasing the infarction size and improve clinical
outcome. Nicorandil was injected immediately after recanalization of
culprit lesion. Timing the injection so it is “before the onset of reperfu-
sion injury” and targeting the point of injection (i.e., “selective
intracoronary injection”) may be key to the beneﬁcial effect that
prevents reperfusion injury and preserves the regionalmicrocirculation.
Additionally, as intracoronary administration of nicorandil did not
reduce the maximum creatine phosphokinase leak, it is possible that it
improved the microcirculation.
Previous reports have indicated thatMBF is reduced in remote areas
in patientswith ischemic heart disease, probably as a result of decreased
coronary vasodilator reserve [26,27]. Early coronary arteriosclerosis and
altered endothelial function also are found before the development of
gross coronary artery disease (CAD) in patients with hyperlipidemia,
diabetes mellitus, and hypertension [28–30]. The present data are
consistent with previous reports. Early microvascular change may
reduce MBF in these segments despite the lack of signiﬁcant stenosis
in major coronary arteries. Ischemic changes and coronary risk factors
might alter endothelial function. Such subtle changes in MBF with PET
can be identiﬁed.
Noninvasive measurement of MBF by 15O-labeled water PET
accurately reﬂects the results of invasive techniques such as
measurements using an intracoronary Doppler guide wire [31]. PETcan compare directly reperfused segments with normal segments si-
multaneously, a capability that is limited when using the intracoronary
Doppler guide wire. PET permits quantitative measurements of MBF,
which generate accurate data about multi-vessel and diffuse CAD.
Therefore, 15O-labeled water PET may detect small regional differences
inMBF and document earlymicrovascular changes sensitively that can-
not be detected by stress perfusion, single-photon emission computed
tomography.
5. Study limitations
The number of subjects in this study was small, so it will be neces-
sary to increase the number of subjects for further comparison of the
two methods. This study is not randomized and double blind, so the
difference in baseline patient characteristics and device might affect
these results. In this study, patients continued to take their usual
medications. We cannot rule out that these medications selectively
affected the coronary vasodilator reserve. Because most of the patients
had severe CAD and were taking several medications, we decided to
continue their usual medications to maintain stable conditions during
the studies. Finally, the deﬁnition of “onset” may vary, which means
that the difference in treatment times may also vary.
6. Conclusions
Noninvasive measurement of myocardial blood ﬂow by PET might
be feasible and valuable for assessing the impact of adjunctive therapy
at the subacute phase in patients with ST-elevation myocardial infarc-
tion. 15O-labeled water PET revealed that the targeted administration
of nicorandil could provide salutary adjunctive therapy to primary PCI
for STEMI by preserving the MBF in the reperfused segments.
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